Echo Therapeutics’ Symphony CGM system has won Medical Devices Business Review’s Medical Device Innovation Award.
Echo’s device was selected from four nominations shortlisted for the award.
Symphony CGM system is a non-invasive (needle-free), wireless, continuous glucose monitoring system.
Echo’s CGM system is a two-part device that monitors blood glucose by taking readings through a patient’s skin rather than via finger pricks, thus eliminating the risks or discomfort associated with needle-based systems.
It incorporates Prelude, Echo’s proprietary skin permeation device, a glucose biosensor patch, a wireless transmitter and a small glucose monitor.
The Prelude SkinPrep system uses a needle-free, painless technology that removes the outermost layer of skin, the stratum corneum, a layer of about 0.01mm in thickness consisting of only dry, dead skin cells.
Prelude is used to permeate the skin before placing the biosensor on the permeated site. Wireless technology is used to send minute-by-minute readings of patient’s glucose level to a remote monitor.
An audible alarm and visual graphics sound an alert when a patient’s glucose level moves outside the target range.
In this way, Symphony will provide continuous access to glucose values and changes, and identifies prolonged excursions into the hyperglycemic or hypoglycemic zones.